A powerful message of health equity reverberated through Raleigh as Rev. Jamal Bryant spearheaded the "Healthy Churches 2030" ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Gilead Sciences (GILD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the ...

GILD opened at $116.04 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 52-week low of $62.07 and a 52-week ...

“The Handmaid’s Tale” opens with and focuses on Offred, aka June Osbourne (Elisabeth Moss), as she seemingly shakes herself out of dumbfounded complacency and into a determination to break free of the ...

Novartis' Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Gilead Sciences' Kite subsidiary is now looming in the rear view mirror – armed ...

The latest analyst rating for Gilead Sciences (NASDAQ:GILD) was provided by Morgan Stanley, and Gilead Sciences maintained their overweight rating. The last upgrade for Gilead Sciences Inc ...

New York: Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into its promotional speakers program for HIV drugs. The ...

Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...